Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registry

Autor:	P.C.M. van de Kerkhof, A.M. Oostveen, Esther P A H Hoppenreijs, Marieke M B Seyger, M. van Geel, Jan C.M. Hendriks, E.M.G.J. de Jong
Rok vydání:	2015
Předmět:	Subset Analysis Male Pediatrics medicine.medical_specialty Adolescent Body Surface Area Dermatology Kaplan-Meier Estimate Single Center Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] Quality of life Psoriasis Area and Severity Index Psoriasis Medicine Humans Longitudinal Studies Prospective Studies Registries Child Body surface area business.industry Anthralin Phototherapy medicine.disease Methotrexate Treatment Outcome Child Preschool Cohort Quality of Life Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] Female Dermatologic Agents business Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] medicine.drug
Zdroj:	Journal of Dermatological Treatment, 26, 5, pp. 406-12 Journal of Dermatological Treatment, 26, 406-12
ISSN:	0954-6634
Popis:	Contains fulltext : 151800.pdf (Publisher’s version ) (Closed access) BACKGROUND: Evidence on effectiveness and safety of methotrexate (MTX) in pediatric psoriasis is scarce. OBJECTIVES: To study the effectiveness and safety of MTX in pediatric plaque-type psoriasis and its influence on quality of life (Qol) in daily clinical practice. METHODS: Subset analysis of prospectively collected data extracted from the Child-CAPTURE registry, a single center, longitudinal, long-term, observational daily practice cohort of pediatric psoriasis patients. A maximum dose between 0.14 and 0.63 mg/kg once weekly was prescribed in 25 children. Primary endpoints were percentages of patients with >/= 75% improvement in the Psoriasis Area and Severity Index (PASI) at week 12 and 24. RESULTS: PASI75 was achieved in 4.3% and 33.3% of patients at week 12 and 24, whereas 40% and 28.6% reached PASI 75 at week 36 and 48. Median PASI and body surface area decreased from 10.0 (range 3.8-42.4) and 11.0 (range 3.5-72.0) at baseline to 4.3 (range 0-19.8) and 2.6 (range 0.0-39.6) at week 24, respectively. Physician Global Assessment improved significantly from 3.0 to 1.2 at week 24. A significant decrease in Children's Dermatology Life Quality Index from 9.0 to 3.8 at week 24 was found. Most reported adverse events were severe nausea (n = 5), infections requiring antibiotics (n = 5) and tiredness (n = 4). CONCLUSIONS: MTX shows a positive effect on PASI scores, improves Qol and has a reasonable safety profile.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39b1bda4c272bae7f29b47ced6587e50 https://hdl.handle.net/2066/151800 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.